News Releases

Oct 02, 2026

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Oct 01, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 01, 2026

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Sep 30, 2026

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Sep 30, 2026

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Sep 10, 2026

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

Sep 01, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 26, 2026

Candel Therapeutics to Present at September Investor Conferences

Aug 13, 2026

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Aug 03, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)